Literature DB >> 3317186

Anterior segment fluorescein angiography in the surgery of immunologically induced corneal and scleral destructive disorders.

P G Watson1.   

Abstract

Since 1975, 51 patients (55 eyes) have required corneal surgery for immunologically induced destructive corneal and scleral disease. Lamellar keratoplasty is the preferred surgical procedure provided the cornea is not perforated. Surgery will not be successful unless any underlying systemic disease or active ocular inflammatory disease has been treated previously. Anterior segment fluorescein angiography has been found useful in detecting those patients who might require surgery, in monitoring the effect of medical therapy and in deciding the extent of the surgical procedure. The advantages and limitations of the technique are discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3317186     DOI: 10.1016/s0161-6420(87)33276-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Practical anterior segment fluorescein angiography.

Authors:  E Fariza; L D Ormerod; T O'Day; J M Celorio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

Review 2.  Optical coherence tomography angiography: a review of current and future clinical applications.

Authors:  Marcus Ang; Anna C S Tan; Chui Ming Gemmy Cheung; Pearse A Keane; Rosa Dolz-Marco; Chelvin C A Sng; Leopold Schmetterer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-09       Impact factor: 3.117

3.  Anterior segment optical coherence tomography imaging in peripheral ulcerative keratitis, a corneal structural description.

Authors:  Clemence Bonnet; Louis Debillon; Saba Al-Hashimi; Florence Hoogewoud; Dominique Monnet; Jean-Louis Bourges; Antoine Brézin
Journal:  BMC Ophthalmol       Date:  2020-05-25       Impact factor: 2.209

4.  Optical coherence tomography angiography in dural carotid-cavernous sinus fistula.

Authors:  Marcus Ang; Chelvin Sng; Dan Milea
Journal:  BMC Ophthalmol       Date:  2016-07-07       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.